Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation

Cancer Immunology, Immunotherapy

Volumn 63, Issue 10, 2014, Pages 1023-1036

  De Keersmaecker, Brenda ^a   Fostier, Karel ^b   Corthals, Jurgen ^a   Wilgenhof, Sofie ^a   Heirman, Carlo ^a   Aerts, Joeri L ^a   Thielemans, Kris ^a   Schots, Rik ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Dendritic cells; Immunomodulatory drugs; Immunotherapy; Lenalidomide; Multiple myeloma; Pomalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; IMMUNOLOGIC FACTOR; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CELL PROLIFERATION; DENDRITIC CELL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROCEDURES;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; DENDRITIC CELLS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 84928583389     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1571-6     Document Type: Article

References (50)

1. Schots R (2011) Recent advances in myeloma treatment. Transfus Apheresis Sci 44:223–229
2. Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res 19:3337–3344
3. Munshi NC, Anderson KC, Bergsagel PL et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117:4696–4700
4. Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521–2526
5. Reichardt VL, Okada CY, Liso A et al (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 93:2411–2419
6. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 6:621–627
7. Rosenblatt J, Avivi I, Vasir B et al (2013) Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 19:3640–3648
8. Hobo W, Strobbe L, Maas F et al (2013) Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 62:1381–1392
9. Meehan KR, Wu J, Bengtson E et al (2007) Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transplant 39:695–703
10. Rapoport AP, Aqui NA, Stadtmauer EA et al (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117:788–797
11. Meehan KR, Talebian L, Tosteson TD et al (2013) Adoptive cellular therapy using cells enriched for NKG2D+ CD3+ CD8+ T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant 19:129–137
12. Nair JR, Carlson LM, Koorella C et al (2011) CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 187:1243–1253
13. Okunishi K, Dohi M, Nakagome K et al (2005) A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 175:4745–4753
14. Beyer M, Kochanek M, Giese T et al (2006) In vivo peripheral expansion of naive CD4+ CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107:3940–3949
15. −/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 72:540–547
16. Feyler S, von Lilienfeld-Toal M, Jarmin S et al (2009) CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144:686–695
17. Van Valckenborgh E, Schouppe E, Movahedi K et al (2012) Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 26:2424–2428
18. Görgün GT, Whitehill G, Anderson JL et al (2013) Tumor promoting immune suppressive myeloid derived suppressor cells in multiple myeloma microenvironment. Blood 121:2975–2987
19. Ramachandran IR, Martner A, Pisklakova A et al (2013) Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 190:3815–3823
20. Lu L, Payvandi F, Wu L et al (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78–86
21. Mitsiades N (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530
22. LeBlanc R, Hideshima T, Catley LP et al (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787–1790
23. Xu Y, Li J, Ferguson GD et al (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:338–345
24. Lu G, Middleton RE, Sun H et al (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343:305–309
25. Lopez-Girona A, Mendy D, Ito T et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326–2335
26. Wilgenhof S, Van Nuffel AMT, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448–456
27. Van Nuffel AMT, Benteyn D, Wilgenhof S et al (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033–1043
28. Bonehill A, Van Nuffel AMT, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366–3375
29. Wilgenhof S, Pierret L, Corthals J et al (2011) Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. Melanoma Res 21:152–159
30. De Keersmaecker B, Heirman C, Corthals J et al (2011) The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol 89:989–999
31. Zhang L, Götz M, Hofmann S, Greiner J (2012) Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol 2012:820394
32. De Keersmaecker B, Allard SD, Lacor P et al (2012) Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol 86:9351–9360
33. Yuan J, Gnjatic S, Li H et al (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415
34. Aranda F, Llopiz D, Díaz-Valdés N et al (2011) Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71:3214–3224
35. + T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 120:2229–2239
36. Galustian C, Meyer B, Labarthe M-C et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033–1045
37. Vasquez-Dunddel D, Pan F, Zeng Q et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123:1580–1589
38. Qin A, Cai W, Pan T et al (2013) Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 87:1477–1490
39. Mougiakakos D, Jitschin R, von Bahr L et al (2012) Immunosuppressive CD14+ HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 27:377–388
40. Poschke I, Mougiakakos D, Hansson J et al (2010) Immature immunosuppressive CD14+ HLA-DR−/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335–4345
41. Kotsakis A, Harasymczuk M, Schilling B et al (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381:14–22
42. Schilling B, Sucker A, Griewank K et al (2013) Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 133:1653–1663
43. Duffy A, Zhao F, Haile L et al (2013) Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother 62:299–307
44. Serafini P, Meckel K, Kelso M et al (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691–2702
45. Bonehill A, Tuyaerts S, Van Nuffel AMT et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170–1180
46. Wilgenhof S, Van Nuffel AMT, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686–2693
47. Maecker B, Anderson KS, von Bergwelt-Baildon MS et al (2003) Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol 121:842–848
48. Sakamaki I, Kwak LW, Cha S-C et al (2014) Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28:329–337
49. Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466–1475
50. Richter J, Neparidze N, Zhang L et al (2013) Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121:423–430